BSX · Earnings call · 2026Q3T · Full report

TIVUS Trial Enrollment and Positioning

BOSTON SCIENTIFIC CORP · 2026-10-28 · Importance 7 · Surprise 24

Enrollment in the TIVUS renal denervation clinical trial has been slower than management hoped, partly as the Relievant team was transitioned and integrated into Boston Scientific. Management said it remains confident enrollment can get back on track and eventually finish. It considers ultrasound the best energy source for renal denervation and believes TIVUS has differentiated advantages over the two currently approved devices for hypertension.

Key facts

• Boston Scientific said TIVUS clinical-trial enrollment had been slower than hoped while it integrated the Relievant team, but it was confident it could get enrollment on track and finish it.
• Boston Scientific believes ultrasound is the best energy source for renal denervation and says TIVUS has differentiated advantages over the two currently approved devices for renal-denervation hypertension.